RxDoctor Payments Data

Alan Schimmel, MD

Cardiovascular Disease · Jacksonville, FLNPI 1710964671

Payments from drug & device makers

$16,156in general payments, 2019–2025

Across 618 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$5K
  • AstraZeneca$1K
  • Novartis$1K
  • Boehringer Ingelheim$957
  • Merck$876
  • Pfizer$786
  • plus $7K from 45 others

What the payments were for

  • Consulting fees$1,3759%
  • Speaking & faculty fees$1,2007%
  • Food & beverage$13,47983%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,156 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$295,466
Medicare patients
1,479
Services billed
3,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$532,989
OpsumitMacitentan22$281,867
EntrestoSacubitril/Valsartan191$266,227
EliquisApixaban194$237,443
JardianceEmpagliflozin115$139,711
FarxigaDapagliflozin Propanediol68$79,032
XareltoRivaroxaban49$59,826
Ranolazine ErRanolazine74$9,238
Metoprolol Succinate705$8,175
Rosuvastatin Calcium394$5,679
Atorvastatin Calcium364$4,670
Losartan Potassium365$3,363
Flecainide Acetate50$3,169
ClopidogrelClopidogrel Bisulfate212$3,048
Prasugrel Hcl26$3,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$786$770,433214 claims
Actelion Pharmaceuticals US, Inc.Opsumit$4,518$281,86722 claims
NovartisEntresto$1,123$266,227191 claims
Boehringer IngelheimJardiance$957$139,711115 claims
AstraZenecaFarxiga$1,299$79,03268 claims
Johnson & JohnsonXarelto$251$59,82649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →